Systemic sclerosis & Raynaud's
The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation
Main finding · Worsening GIT score at follow-up visitResult — go to the resultOdds ratio 3.48 CI 1.22–9.98Authors' conclusion
This report from the CONQUER cohort, suggests that most patients with early SSc have stable and mild GIT disease. Closer follow-up was associated with milder, stable GIT symptoms. There was no clear association between immunosuppression or anti-fibrotic use and severity of GIT symptoms. However, active tobacco use was associated with worse GIT symptoms
Study context
- Population
- US Collaborative National Quality and Efficacy Registry (CONQUER) registry: Systemic Sclerosis (SSc) patients with <5 years disease duration at Scleroderma centres of excellence, with at least two serial gastrointestinal tract (GIT) 2.0 questionnaires
- Participants
- 415 participants
- Exposure
- Current tobacco use and medication exposures vs change in GIT symptom severity
- Outcome
- Change in total GIT 2.0 severity category (none-to-mild, moderate, severe-to-very severe) at the subsequent visit
- Follow-up
- Visit
Methodological detailslongitudinal, multicentre, proportional odds model
- Longitudinal
- Multicentre
- Proportional odds model
Main finding
Worsening GIT score at follow-up visit
Odds ratio
3.48
CI 1.22–9.98
p 0.020
Current tobacco use and medication exposuresvs change in GIT symptom severity
OR 3.48 (CI 1.22–9.98); p 0.020
As reported in the abstract
Observational data: associations, not effects.
Further findings
Timing of medication initiation
- In most patients, anti-reflux and immunosuppression initiation preceded baseline; anti-fibrotic initiation at or after baseline
Original publication
The Collaborative National Quality and Efficacy Registry for Scleroderma: association of medication use on gastrointestinal tract symptoms in early disease and the importance of tobacco cessation. Clin Exp Rheumatol. Published 21 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →